5th Floor, Rajapushpa Summit
Nanakramguda Rd, Financial District, Gachibowli
Hyderabad, Telangana - 500008
The Dermatological Therapeutics Market is segmented by Application (Alopecia, Herpes, Psoriasis, Rosacea, Atopic Dermatitis, and Other Applications), Drug Class (Anti-infectives, Corticosteroids, Calcineurin Inhibitors, Retinoids, and Other Drug Classes), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America).
2018 - 2026
Fastest Growing Market:
With the rise in the aging population, dermatological care is likely to receive particular attention. As people age, the risk of developing skin-related disorders increases, due to factors, such as changes in the connective tissue, reduction in the skin's strength and elasticity, and reduction in secretions from sebaceous glands.
Skin conditions pose a significant threat to patient’s well-being, mental health, ability to function, and social participation. The increasing incidence of dermatological diseases and increasing levels of awareness-related disease progression, etiology, and available therapies are leading to a high growth of dermatological therapeutics.
The dermatological therapeutics market is segmented by application, drug class, and geography. By application, the market is segmented into alopecia, herpes, psoriasis, rosacea, atopic dermatitis, and other applications. By drug class, the market is segmented into anti-infectives, corticosteroids, calcineurin inhibitors, retinoids, and other drug classes. By geography, the market is segmented by North America, Europe, Asia-Pacific, Middle-East and Africa, and South America.
|By Drug Class|
|Other Drug Classes|
Report scope can be customized per your requirements. Click here.
Atopic dermatitis is a widespread chronic inflammatory skin condition that can affect patients of all ages, and it is the result of multiple environmental, immunological, genetic, and pharmacologic factors. The disease mostly flares up when the patient is around the things that cause allergic reactions. The malfunctioning in the immune system of the human body, due to asthma, is also a major cause of atopic dermatitis. Due to several lifestyle factors, the global burden of atopic dermatitis is increasing rapidly, which, in turn, is fueling the growth of the segment.
To understand key trends, Download Sample Report
North America is expected to lead the global market. Increasing healthcare expenditure, awareness about skin diseases, and the strong presence of pharmaceutical companies are anticipated to drive the market growth in North America. In Asia-Pacific, the ever-increasing pool of the patient population, increasing awareness, and increasing disposable incomes are expected to be pivotal to the robust market growth in the region.
To understand geography trends, Download Sample Report.
Many new players are emerging in the dermatological therapeutics market, as a result of a number of growth opportunities. Forthcoming patent expiries of major drugs are leading to increased competition, and it is further driving the market studied, especially in the generic sector. The overall dermatological diagnostics and therapeutics industry is expected to witness tremendous growth, with several generic players controlling significant market share in the developing regions.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Dermatology Diseases
4.2.2 Increase in Awareness Levels of Disease Progression and Etiology
4.2.3 Increase in the Elderly Population
4.3 Market Restraints
4.3.1 Serious Side Effects for Certain Classes of Therapeutic Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Application
5.1.5 Atopic Dermatitis
5.1.6 Other Applications
5.2 By Drug Class
5.2.3 Calcineurin Inhibitors
5.2.5 Other Drug Classes
5.3 By Geography
5.3.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle-East and Africa
5.3.5 South America
184.108.40.206 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Allergan PLC
6.1.3 Amgen Inc.
6.1.4 Almirall SA
6.1.5 Bausch Health Companies Inc.
6.1.6 Galderma SA
6.1.7 GlaxoSmithKline PLC
6.1.8 Johnson & Johnson
6.1.9 Novartis International AG
6.1.10 Pfizer Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments